Company Monitoring Page for Novartis

latest headlines for company on cafepharma

FDA approves Novartis combo therapy for aggressive type of thyroid cancer
Reuters
Fri, 05/4/18 - 06:53 pm
Tags:
Novartis, FDA, Tafinlar, Mekinist, anaplastic thyroid cancer
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Wed, 05/2/18 - 10:00 pm
Tags:
Kymriah, Novartis, cell therapy, Yescarta, Gilead Sciences
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Mon, 04/30/18 - 09:04 pm
Tags:
Novartis, Regeneron, Eylea, RTH258, wet age-related macular degeneration
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
Sat, 04/28/18 - 12:18 pm
Tags:
M&A, Takeda, Shire, Novartis, AveXis, Sanofi, Bioverativ, Celgene, Juno Therapeutics
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
CP Wire
Wed, 04/25/18 - 10:29 pm
Tags:
AveXis, Novartis, M&A, clinical trials, AVXS-101, gene therapy, spinal muscular atrophy
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Endpoints
Sat, 04/21/18 - 12:44 pm
Tags:
Novartis, cancer, Pharma CEOs, Vas Narasimhan
Novartis pads case for new MS blockbuster with disease-progression analysis
Fierce Pharma
Sat, 04/21/18 - 12:41 pm
Tags:
Novartis, MS, multiple sclerois, siponimod
Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
Fierce Pharma
Fri, 04/20/18 - 10:00 am
Tags:
Novartis, GSK, Advair, asthma
[video]Did Novartis Overpay for AveXis?
Motley Fool
Mon, 04/16/18 - 11:34 pm
Tags:
Novartis, AveXis, gene therapy, M&A
Q1 kicks off with J&J, Novartis, Glaxo results
Biopharma Dive
Sun, 04/15/18 - 09:48 pm
Tags:
earnings, JNJ, Novartis, GSK
3 Biotech Stocks That Soared This Week
Motley Fool
Sat, 04/14/18 - 12:37 pm
Tags:
AveXis, Abeona Therapeutics, Spectrum Pharmaceuticals, Novartis, M&A, poziotinib, EB-101
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
Forbes
Thu, 04/12/18 - 11:49 am
Tags:
Novartis, Pharma CEOs, FDA, drug pricing, Vasant Narasimham
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Wed, 04/11/18 - 09:32 am
Tags:
Novartis, Oncology Venture, dovitinib, kidney cancer, cancer
Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study
Fierce Pharma
Tue, 04/10/18 - 10:30 pm
Tags:
physician payments, Novartis, Pfizer, Bayer, Bristol-Myers Squibb, cancer
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
Forbes
Mon, 04/9/18 - 03:31 pm
Tags:
Novartis, Vas Narasimhan, M&A, gene therapy, AveXis
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Marketwatch
Mon, 04/9/18 - 09:10 am
Tags:
Novartis, AveXis, Biogen, SMA, M&A, AVXS-1-1, Spinraza
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Mon, 04/9/18 - 09:00 am
Tags:
Novartis, M&A, AveXis, gene therapy, AVXS-101, SMA, spinal muscular atrophy
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Fierce Pharma
Fri, 04/6/18 - 11:24 am
Tags:
Novartis, China, Greece, kickbacks, bribery
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Thu, 04/5/18 - 11:57 pm
Tags:
Conatus Pharmaceuticals, clinical trials, Novartis, emricasan, liver disease, hepatitis C
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Investors Business Daily
Fri, 03/30/18 - 09:26 am
Tags:
Novartis, Amgen, Enbrel, biosimilars

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.